Cookies

Like most websites The Pathologist uses cookies. In order to deliver a personalized, responsive service and to improve the site, we remember and store information about how you use it. Learn more.
Subscribe to Newsletter

Precision medicine

Diagnostics Genetics and epigenetics

The Right Dose for the Right Person

| Michael Schubert

New guidelines for CYPC29 genotyping ensure that the correct alleles are tested and patients are prescribed the correct doses of common drugs

Inside the Lab Digital and computational pathology

Long Live the (Digital) Revolution!

| Dariusz Borys

Pathology’s great strides forward in artificial intelligence and machine learning will bring us to the forefront of personalized medicine

Diagnostics Biochemistry and molecular biology

A Disease With Many Faces

| David R. Hout

Triple-negative breast cancer is not a single entity, and understanding each patient’s molecular subtype can influence treatment and outcomes

Inside the Lab Precision medicine

Next-Generation Sequencing: Will It Really Replace Single-Gene Tests in Pathology Labs?

| Sponsored by Thermo Fisher Scientific

The move to in-house next-generation sequencing has resulted in time and tissue savings, and improved collaboration across cancer care specialties

Diagnostics Digital and computational pathology

Biosensors for the Future

| Luke Turner

From a new material for lung cancer diagnosis to real-time robotics for monitoring reproductive hormones, discover our latest bite-sized breakthroughs

Subspecialties Clinical care

An Inside Look at the CNS

| Danielle Fortuna, Mark Curtis

Neurological disorders can be invasive and time-consuming to diagnose, but profiling cytokines in the cerebrospinal fluid can lessen that burden

Inside the Lab Clinical care

Positive Steps to Tackle Triple-Negative Breast Cancer

| Jane Armes

Jane Armes discusses the value of molecular subtyping and targeted therapies in triple-negative breast cancer

Inside the Lab Biochemistry and molecular biology

A Fluid Future

| Luke Turner

Liquid biopsy has shown promise as a rapid, minimally invasive way to profile tumors – but are commercially available tests accurate and consistent?

Subspecialties Genetics and epigenetics

Putting a Bug in Your Ear

| Michael Schubert

Variants in the FUT2 gene may increase susceptibility to otitis media by altering the microbiome of the middle ear

Diagnostics Liquid biopsy

A Diagnostic to Drool Over?

| Luke Turner

The use of saliva as a diagnostic fluid seems an attractive option – especially now that research reveals circulating tumor DNA in the fluid

Register to The Pathologist

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Pathologist magazine

Register